Abstract
In different clinical studies, an association of type 2 diabetes and Alzheimers disease (AD) has been described. However, the underlying mechanisms are still unclear. One explanation could be that vascular complications of diabetes result in neurodegeneration. Alternatively, the mechanism might be directly related to insulin and insulin-like growth factor( IGF)-1 signaling, leading to the proposal that AD is a “brain-type diabetes”. Furthermore, postmortem analyses of brains from patients with AD revealed a markedly downregulated expression of insulin receptor (IR), IGF-1 receptor (IGF-1R), insulin receptor substrate (IRS)-1 and IRS-2, and these changes progress with severity of neurodegeneration. These findings raise the question, whether this phenomenon is cause or consequence of neurodegeneration. Recently, Cohen and coworkers have show that knocking down DAF-2 in C. elegans, the homolog of the mammalian IR/IGF-1R, reduces β-amyloid(Aβ)1-42 toxicity. Cell based experiments suggest a specific role for the IGF-1/IRS-2 signaling pathway in regulating α-/β-secretase activity. Moreover circulating IGF-1 might influence Aβ clearance from the brain by promoting Aβ transport over the blood brain barrier. Interestingly, brain specific deletion of IRS-2 increases life span, suggesting that long term neuronal IGF-1R signaling might be harmful. Taken together, the data from humans and different model organisms indicate a role of IR/IGF-1R signaling in Aβ metabolism, and clearance as well as longevity. Since more studies are needed to elucidate the impact of insulin and/or IGF-1 treatment in AD, the time to propose these hormones as a potential treatment option for AD has not come yet.
Keywords: Insulin receptor, IGF-1 receptor, Alzheimer's disease
Current Alzheimer Research
Title: The Role of IGF-1 Receptor and Insulin Receptor Signaling for the Pathogenesis of Alzheimers Disease: From Model Organisms to Human Disease
Volume: 6 Issue: 3
Author(s): S. Freude, K. Schilbach and M. Schubert
Affiliation:
Keywords: Insulin receptor, IGF-1 receptor, Alzheimer's disease
Abstract: In different clinical studies, an association of type 2 diabetes and Alzheimers disease (AD) has been described. However, the underlying mechanisms are still unclear. One explanation could be that vascular complications of diabetes result in neurodegeneration. Alternatively, the mechanism might be directly related to insulin and insulin-like growth factor( IGF)-1 signaling, leading to the proposal that AD is a “brain-type diabetes”. Furthermore, postmortem analyses of brains from patients with AD revealed a markedly downregulated expression of insulin receptor (IR), IGF-1 receptor (IGF-1R), insulin receptor substrate (IRS)-1 and IRS-2, and these changes progress with severity of neurodegeneration. These findings raise the question, whether this phenomenon is cause or consequence of neurodegeneration. Recently, Cohen and coworkers have show that knocking down DAF-2 in C. elegans, the homolog of the mammalian IR/IGF-1R, reduces β-amyloid(Aβ)1-42 toxicity. Cell based experiments suggest a specific role for the IGF-1/IRS-2 signaling pathway in regulating α-/β-secretase activity. Moreover circulating IGF-1 might influence Aβ clearance from the brain by promoting Aβ transport over the blood brain barrier. Interestingly, brain specific deletion of IRS-2 increases life span, suggesting that long term neuronal IGF-1R signaling might be harmful. Taken together, the data from humans and different model organisms indicate a role of IR/IGF-1R signaling in Aβ metabolism, and clearance as well as longevity. Since more studies are needed to elucidate the impact of insulin and/or IGF-1 treatment in AD, the time to propose these hormones as a potential treatment option for AD has not come yet.
Export Options
About this article
Cite this article as:
Freude S., Schilbach K. and Schubert M., The Role of IGF-1 Receptor and Insulin Receptor Signaling for the Pathogenesis of Alzheimers Disease: From Model Organisms to Human Disease, Current Alzheimer Research 2009; 6 (3) . https://dx.doi.org/10.2174/156720509788486527
DOI https://dx.doi.org/10.2174/156720509788486527 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
Current Cancer Therapy Reviews Antiviral Immunotherapy for Mosquito-Borne Flaviviruses: A Review of Current Status
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Pyrimidine-fused Dinitrogenous Penta-heterocycles as a Privileged Scaffold for Anti-Cancer Drug Discovery
Current Topics in Medicinal Chemistry Subject Index To Volume 12
Current Pharmaceutical Design Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise
Current Pharmaceutical Design Emerging Molecular Functions of MicroRNA-9: Cancer Pathology and Therapeutic Implications
Anti-Cancer Agents in Medicinal Chemistry Cell Survival Signaling in Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry CNS Immune Surveillance and Neuroinflammation: Endocannabinoids Keep Control
Current Pharmaceutical Design Recent Pharmacoproteomics Studies of Warfarin in the Asia-Pacific: A New Strategy for Personalized Medicine?
Current Pharmacogenomics and Personalized Medicine Curcumin: A Potential Neuroprotective Agent in Parkinson's Disease
Current Pharmaceutical Design Plant Troponoids: Chemistry, Biological Activity, and Biosynthesis
Current Medicinal Chemistry On the Role of Rab5 in Cell Migration
Current Molecular Medicine Nitric Oxide Synthases and Their Natural Inhibitors
Current Enzyme Inhibition Oxaliplatin-mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel
Current Cancer Drug Targets MAPKs and Their Inhibitors in Neuronal Differentiation
Current Enzyme Inhibition Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of Neuroendocrine Prostate Cancer
Current Pharmaceutical Design Multiple Protective Functions of Sigma1 Receptor
Current Protein & Peptide Science Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Cancer Stem-Cells Patents in the Context of their Therapeutic Purposes: Exploring the Latest Trends (2011-2015)
Recent Patents on Regenerative Medicine Bv8-Prokineticins and their Receptors: Modulators of Pain
Current Pharmaceutical Biotechnology